

Iowa Medicaid Pharmaceutical and Therapeutics Committee Minutes

Date: April 21, 2022

Chairperson: Mark Graber, M.D.

Erin Halverson, IME staff, assisted in running the meeting with the Chairperson due to the virtual format.

Time: 9:30 a.m. to 12:04 p.m.

Location: WebEx Teleconference (Due to federal PHE Declaration for the COVID-19 Pandemic)

Committee Members Present: Mark Graber, M.D.; Charles Wadle, D.O.; Abby Cate, Pharm.D.; Jason Kessler, M.D.; Rachel Reinsvold, Pharm.D.; and Mylo Wells, Pharm.D. (Vacancies July 2021: 1 Physician, 1 Physician Assistant)

Iowa DHS Staff Present: Susan Parker, Pharm.D., Pharmacy Consultant; and Krissa Mason, Assistant Attorney General.

Iowa Medicaid Enterprise (IME) Staff Present: Lauren Biczak, D.O.; Erin Halverson, R.Ph.; Gina Kuebler, R.Ph.; Pam Smith, R.Ph.; and Melissa Biddle.

Managed Care Organization (MCO) Staff Present: Emily Rogers, Iowa Total Care.

Chairperson Mark Graber called the meeting to order.

- I. Mark Graber asked that each committee and DHS and IME staff member introduce themselves to the public. Abby Cate made the motion to approve the April minutes, and Chuck Wadle seconded. The motion passed with no objections. There were no new verbal conflict of interest disclosures.
- II. Committee Elections: Mark Graber nominated Jason Kessler as Chairperson, but he declined, saying he'd like more experience on the committee prior to taking that position. Mark Graber then made a motion to retain Chuck Wadle as Vice-Chairperson. Abby Cate seconded, and all members were in favor. Mark Graber also agreed to continue as Chairperson for another year, given the lack of additional nominations. Everyone was in agreement on this, as well.
- III. Review of P&T Policy & Procedure – General Update and Interim PDL Changes (Erin Halverson): Chuck Wadle motioned to accept the proposed changes, and Mylo Wells seconded. The decision was unanimous.
- IV. PDL Revision Notifications (Erin Halverson): The fax blasts sent to providers since the last P&T Meeting in April, to notify them of preferred drug list changes, were reviewed. There was only one since November, for Chantix effective January 21, 2022, due to availability issues for the brand.
- V. Drug Rebate Issues (Dr. Biczak): The SSDC drug pool increased the covered lives by 1.7 million from 2021 to 2022, and also increased the covered drug spend to \$13.1 billion. This will help give the SSDC more negotiating power. The bid process for next year has begun, with letters for

supplemental rebates and durable medical supplies sent out on March 7, 2022. Offers will be received until April 22, 2022, and then the SSDC will meet for the annual meeting in July to review the offers with the pool states.

- VI. PA Criteria/Pro-DUR Edits (Dr. Parker): Susan Parker reviewed the informational letters that had been sent out since the last P&T Meeting in April, all posted online at http://iowamedicaidpdl.com/informational_letters and http://iowamedicaidpos.com/latest_news. Informational Letter 2280-MC-FFS-D contained Federal provider requirements for prescribing controlled substances for Medicaid members, as section 5042 of the Substance Use-Disorder Prevention that Promotes Opioid Recovery and Treatment (SUPPORT) for Patients and Communities Act, codified in 42 U.S.C. 1396w-3a, requires covered providers who are permitted to prescribe controlled substances and who participate in Medicaid to query qualified prescription drug monitoring programs (PDMPs) before prescribing controlled substances to most Medicaid beneficiaries. Providers received Informational Letter 2291-MC-FFS related to PDL and prior authorization criteria changes that went into effect January 1, 2022, following the November P&T and DUR Meetings. Information Letter 2305-MC-FFS-CVD details pharmacy program coverage for oral COVID-19 therapeutics. Informational Letter 2306-MC-FFS notified providers of the 2022 pharmacy cost of dispensing survey, for which surveys were sent out to providers on February 2, 2022, and due back by March 30, 2022. The committee also received copies of the letters sent to the Department of Human Services from the DUR Commission after their February meeting, which included recommendations for: Select Preventative Migraine Treatments; Hepatitis C Treatments, Direct Acting Antivirals; Janus Kinase Inhibitors; Apremilast (Otezla); Biologicals for Arthritis; Triheptanoin (Dojolvi); and Baclofen Oral Solution (Ozobax).
- VII. Legislation (Dr. Parker): There were no updates. The Iowa legislature is still in session.
- VIII. IME Updates: Mark Graber, Erin Halverson, Laureen Biczak, and Susan Parker all noted the tragic passing of Steve Liles, and his many contributions to this committee and the state as a pharmacy consultant for the IME and Senior Director for Change Healthcare for the last 10 years. His immense clinical pharmaceutical knowledge and dry wit will be missed by all.
- IX. Public Comment: As this meeting was purely virtual, only written public comment was accepted. The committee members reviewed the received comments, which are posted at: <http://www.iowamedicaidpdl.com/public-comments>. They were also forwarded manufacturer comments as they were received via email prior to the meeting.

Provider Comments Received:
Skytrofa

Manufacturer Comments Received:
Scemblix, Livmarli, Skytrofa, Tavneos, Qulipta, Adbry, Lybalvi, Recorlev, Ozempic, Briviact, Nayzilam, Carbaglu

At 9:54, Abby Cate motioned to go to closed session as authorized by Iowa Code Section 21.5(1)(a) of the Open Meetings Law to review or discuss economic records associated with the PDL which are required or authorized to be kept confidential. The motion passed with unanimous roll call approval. Open session resumed at 10:45.

X. PDL Discussion and Deliberation (Erin Halverson): All subsequent recommendations (with numbering as provided on agenda attachment 2) were made to maximize cost savings to the program unless otherwise noted. Voting was done in four separate blocks due to the volume of proposed changes.

1. Carbamazepine oral suspension to Preferred.
2. Tegretol oral suspension to Non-Preferred (grandfather established users with seizure diagnosis).
3. Deferisirox sol tablets (generic Exjade) to Preferred with Conditions.
4. Exjade to Non-Preferred with Conditions.
5. Ancobon to Non-Preferred with Conditions.
6. Vfend oral suspension to Preferred with Conditions.
7. Voriconazole oral suspension to Non-Preferred with Conditions.
8. Vfend IV sol to Non-Preferred with Conditions.
9. Voriconazole IV sol to Preferred with Conditions.
10. Caspofungin to Preferred with Conditions.

Rachel Reinsvold motioned to accept the recommendations above, and Abby Cate seconded. The decision was unanimous.

11. Cancidas to Non-Preferred with Conditions.
12. Micafungin sol to Preferred with Conditions (brand Mycamine discontinued).
13. Xeljanz to Preferred with Conditions.
14. Otezla to Preferred with Conditions.
15. Tazarotene cream to Preferred with Conditions (brand Tazorac not rebate eligible).
16. Invanz to Non-Preferred.
17. Ertapenem to Preferred.
18. Carnitor SF oral solution to Non-Preferred.
19. Levocarnitine oral solution to Preferred.
20. Colesevelam tablets to Preferred.

Rachel Reinsvold motioned to accept the recommendations above. Jason Kessler and Mylo Wells both seconded. The decision was unanimous.

21. Welchol tablets to Non-Preferred.
22. Lotronex to Non-Preferred.
23. Alosetron to Preferred.
24. Dexilant to Non-Preferred with Conditions.
25. Esomeprazole magnesium capsules to Preferred.
26. Lansoprazole capsules to Preferred.
27. Protonix oral packet to Preferred.
28. Rabeprazole to Preferred.
29. Harvoni Oral Packet 33.75-150mg to Non-Preferred with Conditions.
30. Harvoni 45-200mg tab to Non-Preferred with Conditions.

Mylo Wells motioned to accept the recommendations above, and Chuck Wadle seconded. The decision was unanimous.

31. Epclusa 200-50mg tab to Non-Preferred with Conditions.
32. Paricalcitol capsules to Preferred.
33. Zemplar capsules to Non-Preferred.
34. Mestinon Timespan to Non-Preferred.
35. Pyridostigmine ER tablets to Preferred.
36. Cogentin injection to Non-Preferred.
37. Benztropine injection to Preferred.
38. Bosentan tablets to Preferred with Conditions.
39. Tracleer tablets to Non-Preferred with Conditions.
40. Liothyronine tablets and IV sol to Preferred (Cytomel remains Preferred).
41. Triostat to Non-Preferred.
42. Clindamycin phosphate-benzoyl peroxide 1.2-2.5% to Preferred with Conditions.
43. Acanya to Non-Preferred with Conditions.
44. Protopoc ointment to Non-Preferred with Conditions.
45. Tacrolimus ointment to Preferred with Conditions.

Jason Kessler motioned to accept the recommendations above, and Rachel Reinsvold seconded. The decision was unanimous.

- XI. RDL Discussion and Deliberation (Erin Halverson): All subsequent recommendations (with numbering as provided on agenda attachment 3) were made to maximize cost savings to the program unless otherwise noted.

1. Tarceva to Non-Preferred with Conditions.
2. Erlotinib to Preferred with Conditions.
3. Kaletra to Non-Preferred.
4. Lopinavir-ritonavir to Preferred.

Abby Cate motioned to accept the recommendations above, and Mylo Wells and Rachel Reinsvold both seconded. The decision was unanimous.

- XII. Newly Released Drugs (Dr. Biczak): All following recommendations (with numbering as provided on agenda attachment 4) were made to maximize cost savings to the program unless otherwise noted. Voting was done in two separate blocks due to the volume of new drugs being reviewed. Complete new drug monographs can be found on the April meeting page at http://iowamedicaidpdl.com/schedule_page/april-21-2022. Dr. Biczak reviewed the new drugs, and the recommendations were as follows:

1. Adbry- Recommend status on the PDL as Non-Preferred
2. Exkivity- Recommend status on the RDL as Non-Recommended with Conditions
3. Livmarli- Recommend status on the PDL as Non-Preferred
4. Livtency- Recommend status on the PDL as Non-Preferred
5. Lybalvi- Recommend status on the PDL as Non-Preferred Step 3
6. Opzelura- Recommend status on the PDL as Non-Preferred
7. Qulipta- Recommend status on the PDL as Non-Preferred with Conditions
8. Recorlev- Recommend status on the PDL as Non-Preferred
9. Rezurock- Recommend status on the PDL as Non-Preferred
10. Scemblix- Recommend status on the RDL as Non-Recommended with Conditions

Rachel Reinsvold motioned to accept the recommendations above, and Chuck Wadle seconded. The decision was unanimous.

- 11. Skytrofa- Recommend status on the PDL as Non-Preferred with Conditions
- 12. Tavneos- Recommend status on the PDL as Non-Preferred
- 13. Tyrvaya- Recommend status on the PDL as Non-Preferred
- 14. Voxzogo- Recommend status on the PDL as Non-Preferred
- 15. Welireg- Recommend status on the RDL as Non-Recommended with Conditions

Abby Cate motioned to accept the recommendations above, and Jason Kessler seconded. The decision was unanimous.

XIII. Newly Released Generic Drugs (Erin Halverson): All following recommendations were made to maximize cost savings to the program unless otherwise noted.

Drug Name	PDL/RDL Recommendation
Brimonidine/Timolol Ophth Sol	Non-Preferred
Carglumic Acid	Non-Preferred
Cortrophin Inj Gel	Non-Preferred with Conditions
Dexlansoprazole	Non-Preferred with Conditions
Difluprednate Ophth	Non-Preferred
Glycopyrrolate Oral Soln	Non-Preferred
Insulin Glargine Pen	Non-Preferred
Insulin Glargine Vial	Non-Preferred
Naloxone Nasal Spray	Preferred (labeler 00781)
Nebivolol	Non-Preferred with Conditions
Varenicline	Preferred

Jason Kessler motioned to accept the recommendations above. Mylo Wells seconded, and all members were in favor.

XIV. New Drug Dosage Forms/Strengths/Combinations/BioSimilar (Erin Halverson): All following recommendations were made to maximize cost savings to the program unless otherwise noted.

Drug Name	PDL/RDL Recommendation
Elyxyb Oral Soln	Non-Preferred with Conditions
Eprontia Oral Soln	Non-Preferred with Conditions
Loreev XR	Non-Preferred with Conditions
Sertraline Caps	Non-Preferred with Conditions
Trudhesa Nasal- Aerosol Soln	Non-Preferred
Vuity	Non-Preferred
Xarelto Oral Suspension	Non-Preferred with Conditions

Abby Cate motioned to accept the recommendations above. Rachel Reinsvold seconded, and all members were in favor.

A motion was made by Abby Cate to adjourn the meeting. It was seconded by Chuck Wadle, and all in attendance approved. The meeting adjourned at 12:04 p.m. The next scheduled meeting is tentatively set for August 18, 2022.